Invion (ASX: IVX) just unlocked the door to 80% of skin cancers — here is what the data shows so far

Invion Limited (ASX: IVX) has advanced its non-melanoma skin cancer clinical trial into its final stage, with the company’s Safety Review Committee approving an expansion of the patient population to include individuals with basal cell carcinoma (BCC), the most prevalent form of skin cancer and a disease representing roughly 80% of all skin cancer diagnoses globally. The expansion follows a second set of preliminary data from a new cohort of six squamous cell carcinoma (SCC) patients, which confirmed no dose-limiting toxicities, measurable reductions in lesion size relative to baseline, and complete resolution in select cases. Invion, a Melbourne-based clinical-stage life sciences company developing the Photosoft photodynamic technology platform, is now positioned to generate the first human BCC data for INV043, a candidate it is advancing simultaneously across skin cancer and anogenital indications. Invion Limited shares were trading at approximately A$0.067 ahead of this announcement, near the lower end of a 52-week range of A$0.056 to A$0.200, with a market capitalisation of around A$6.5 million.

What does the expansion into basal cell carcinoma mean for Invion’s INV043 development pathway and addressable market?

The significance of this regulatory step within the trial structure is easier to appreciate when the biology of basal cell carcinoma is considered alongside the constraints it imposes on conventional drug development. BCCs are notoriously difficult to replicate in animal models, which has historically limited the ability to build a pre-clinical case for new treatments in this indication before moving into human studies. Invion could not initiate the BCC cohort until satisfactory safety results had been demonstrated in SCC patients. The Safety Review Committee’s approval to expand is therefore not a routine administrative step. It is a gating event that unlocks both the next phase of the trial and, more importantly, the much larger segment of the non-melanoma skin cancer patient population that BCCs represent.

From a commercial standpoint, the addressable market implications are material. BCCs account for the overwhelming majority of skin cancer diagnoses. In the United States alone, an estimated 3.6 million new BCC cases are recorded annually. If INV043 can demonstrate efficacy in this cohort, the eventual commercial pathway extends well beyond squamous cell carcinoma, which, while clinically significant, represents a substantially smaller patient pool. For a company of Invion’s current scale, successfully completing the BCC cohort and generating clean human efficacy and safety data would represent the most important de-risking event the INV043 program has achieved so far.

What do the second SCC cohort results actually show, and how do they compare to what competitors are achieving in photodynamic therapy for skin cancer?

The data released alongside this announcement comes from a new cohort of six SCC patients and should be understood as preliminary and unaudited. That caveat matters. The patient numbers are small, the trial is still in its early phases, and complete resolution data carries a durability qualification because monitoring is ongoing. With those boundaries set, the results are nonetheless coherent with the first cohort findings and incrementally informative on several dimensions.

The absence of dose-limiting toxicities or treatment-related safety concerns across both cohorts is the most commercially relevant data point in this release, because it directly addresses one of the principal criticisms of conventional photodynamic therapy. Existing approved PDT treatments are associated with significant patient discomfort during light activation, and the pain associated with treatment remains a limiting factor in clinical uptake. Clinician feedback from the Invion trial to date describes no pain during or after treatment, a characteristic that differentiates the INV043 topical formulation if it holds through the BCC cohort and into larger studies. The trial data also recorded statistically significant reductions in lesion size relative to baseline at a p-value below 0.05, and the fluorescence signals observed using violet light at 405 nanometres have continued to validate what Invion refers to as the theragnostic potential of the technology, meaning the ability to use the same compound both to visualise and to treat lesions using different light wavelengths.

The broader competitive context is worth noting. An application to expand an existing photodynamic therapy agent for superficial basal cell carcinoma is currently before the FDA, with a decision expected in September 2026, and clinical data from that programme showed complete histological and clinical clearance in roughly 65% of patients treated versus under 5% in the placebo group. This gives a sense of what the regulatory and clinical bar looks like for a PDT agent seeking a BCC indication in a major market. Invion’s INV043 programme is at an earlier stage and cannot be directly compared on clearance rates yet, but the competitive landscape underscores why the pain-free profile and theragnostic differentiation matter. If INV043 can add a cleaner tolerability profile to efficacy outcomes in the BCC range, that would be a credible basis for a Phase II positioning argument.

How does the INV043 anogenital trial connection strengthen or complicate the overall development strategy for Invion Limited?

Invion’s Executive Chair and Chief Executive Officer, Professor Thian Chew, has explicitly linked the NMSC trial data to the company’s upcoming anogenital indication study, noting that the same topical formulation of INV043 will be used. This is a deliberate platform argument: favourable safety and tolerability data in NMSC provides a clinical rationale for regulators, ethics committees, and future partners to take the anogenital trial more seriously from the outset. The logic is defensible. Topical treatment with a compound that has demonstrated no adverse effects and no pain across multiple patient cohorts in a skin cancer setting is a meaningful starting point for a new indication where patient tolerance is an especially sensitive variable.

The risk in this framing is that it raises expectations across two programmes simultaneously. If the BCC cohort produces mixed or weaker-than-expected data, the reputational drag extends beyond the skin cancer programme to any trial that has been positioned as benefiting from the same platform. Invion is a small company operating with limited cash, four employees on record, and a market capitalisation that gives it effectively no margin for setback without a capital raise. The positive formulation read-across argument is strategically sound, but the execution dependency between the two programmes is a concentration risk that investors should not set aside.

What does Invion Limited’s current share price and market position reflect about investor assessment of INV043’s development prospects?

As of early April 2026, Invion Limited shares were trading at approximately A$0.07, within a 52-week range of A$0.05 to A$0.20, and with a market capitalisation of around A$6.5 million. A share price sitting at the lower third of its 12-month trading band ahead of what the company has described as a value-enhancing milestone is a useful signal about how the market is pricing clinical-stage risk at Invion’s development phase. The stock’s 52-week high of A$0.20 is roughly three times the current level, suggesting there have been periods of elevated speculation, likely correlated with prior announcements from the SRC and from earlier SCC cohort data.

The tension for any ASX-listed clinical-stage biotech at this size is that announcements like this one, which are genuinely positive in terms of trial progression, can be difficult to monetise in the short term unless they are accompanied by partnership signals, capital events, or Phase II timelines that institutional investors can anchor to. The BCC cohort expansion is a necessary clinical milestone, but it pushes the timeline for any pivotal data further out. Invion will need to recruit BCC patients, treat and monitor them, and generate the data before a Phase II programme can be credibly scoped and funded. For a company with Invion’s current financial profile, that sequence carries real execution risk even in the absence of any safety issue.

What are the theragnostic and platform implications of Invion’s dual-wavelength approach for INV043 beyond non-melanoma skin cancer?

The fluorescence-based visualisation capability that Invion describes in the INV043 data deserves attention beyond its trial-stage utility. The ability to use one compound both therapeutically and diagnostically, with red light at 660 nanometres triggering the treatment effect and violet light at 405 nanometres enabling visualisation of lesion boundaries, is a structural advantage in cancer management because it directly addresses the challenge of ensuring complete lesion coverage without unnecessary damage to surrounding tissue.

Photodynamic therapy has demonstrated 90% complete clearance rates in superficial basal cell carcinoma while preserving surrounding tissue, an outcome that is particularly valued when lesions are located in cosmetically sensitive areas. INV043’s dual-wavelength design, if it can deliver equivalent clearance with better tolerability, would position it favourably within a global PDT market projected to expand at a compound annual growth rate of above 7% through to 2031, driven by rising skin cancer prevalence and growing reimbursement recognition of PDT’s cost-effectiveness relative to surgery. For Invion, the theragnostic angle is also the most intellectually distinctive part of the pitch to potential licensing or co-development partners, because it offers a value proposition that existing approved agents do not provide in the same integrated way.

What happens next in the Invion INV043 trial timeline and what milestones should the market watch for in the second half of 2026?

Invion has indicated it will now initiate recruitment for the BCC cohort while continuing to treat and monitor participants from the current SCC cohort to build out the durability data on complete resolution cases. The company has committed to further updates as the trial progresses. The key watch points from this point are the pace of BCC patient recruitment, any interim safety readout from the expanded cohort, and whether the anogenital trial formally commences before the end of the calendar year. Each of these events would represent an incremental de-risking of the overall INV043 platform, and any one of them arriving with clean data would likely test the A$0.20 upper end of the recent trading range again.

The institutional test will come when Invion reaches the point where Phase II design and funding need to be addressed. A small company generating encouraging Phase I safety and early efficacy data in two skin cancer subtypes, with a pain-free profile and a theragnostic differentiator, has a credible story to tell in partnering conversations. Whether that story is sufficient to attract the kind of capital required to run a properly powered Phase II without significant dilution remains the central strategic question that this announcement, positive as it is, does not yet answer.

Key takeaways: What Invion’s INV043 basal cell carcinoma expansion means for the company, competitors, and the skin cancer treatment landscape

• The Safety Review Committee’s approval to expand the non-melanoma skin cancer trial to basal cell carcinoma patients is a gating milestone, not a routine step. It was conditional on satisfactory SCC safety data and unlocks access to the largest segment of the skin cancer market.
• Basal cell carcinoma accounts for approximately 80% of all skin cancer diagnoses. Successfully generating human BCC efficacy and safety data with INV043 would represent the most significant commercial de-risking event in the programme’s history.
• The second SCC cohort data shows statistically significant lesion size reductions (p less than 0.05) and complete resolution in select cases. Durability is still under evaluation, and the patient numbers remain small.
• The consistently pain-free treatment profile across both SCC cohorts is clinically significant and differentiates INV043 from existing approved photodynamic therapy treatments, which are associated with meaningful patient discomfort during light activation.
• The dual-wavelength theragnostic capability, using red light for treatment and violet light for visualisation, is the most technically distinctive element of the INV043 platform and the most likely basis for a partnering pitch as the programme matures.
• Invion has linked the NMSC trial data to the upcoming anogenital indication study, which will use the same topical formulation. This creates a platform read-across argument that strengthens both programmes if BCC data holds, but also creates cross-programme concentration risk if it does not.
• Invion shares were trading near A$0.067 ahead of this announcement, in the lower third of a 52-week range of A$0.056 to A$0.200. The market is pricing clinical-stage risk at this scale; a Phase II pathway with clear funding visibility would likely be the catalyst for a sustained re-rating.
• The competitive landscape is tightening. An FDA decision on an expanded photodynamic therapy indication for superficial basal cell carcinoma is expected in September 2026. Invion’s window to establish clinical differentiation before that market signal crystallises is relevant to its licensing and partnership strategy.
• BCC animal model limitations historically constrained early-stage development in this indication. Invion’s ability to move directly to human BCC data on the strength of SCC results is a structural advantage in building an evidence base efficiently.
• The next material catalysts are BCC patient recruitment pace, any interim BCC safety readout, and formal commencement of the anogenital trial. Each carries independent de-risking value for the Photosoft platform beyond the NMSC programme.